Board of Regents Patent applications |
Patent application number | Title | Published |
20150192800 | OPTIMIZATION OF LIGHT FILTERS AND ILLUMINANTS AND PRODUCTS DERIVED THEREFROM - The invention is directed to improved methods of optimizing light for therapeutic or well-being effects. The invention also provides materials, methods, computer programs and systems for the creation and use of optimized Sight filters and illuminants. The methods of the present invention also include the use of optimized light filters and illuminants for use in treating diseases sensitive to modulation of intrinsically photosensitive retinal ganglion cells. The usefulness of the present method is that it results in the treatment of diseases and/or conditions related to light. | 07-09-2015 |
20150110862 | Sweet Gum Fruit Extract as a Therapeutic Agent - Sweet gum ( | 04-23-2015 |
20140155397 | EMT SIGNATURES AND PREDICTIVE MARKERS AND METHOD OF USING THE SAME - EMT signatures and markers useful for characterizing the status of epithelial cancers and for predicting drug responses in patients having non-small cell lung cancer are provided together with methods of using the same. | 06-05-2014 |
20110124585 | Dimeric Small Molecule Potentiators of Apoptosis - Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of The compoundic mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology. | 05-26-2011 |
20100040554 | CONJUGATES OF PHOTO-ACTIVATABLE DYES - A new class of photoactivatable dyes provides the ability to study cell-cell communication in live animals non-invasively with high spatiotemporal resolution. The compositions are made up of a macromolecule, a caging group, and a coumarin dye. Upon photolysis, the coumarin dye is released from the macromolecule caging group complex and is freely diffusible in cells and between cells. The compositions are retained in cells very well, having no observable side effects, no susceptibility to metabolism, and the ability to generate bright fluorescence signals after photolysis. Because of their high loading capacity and long cellular retention, they can be selectively uncaged in specific cells. | 02-18-2010 |
20100021888 | Screening for disease susceptibility by genotyping the CCR5 and CCR2 genes - Provided are compositions, methods and uses for identifying persons at an increased risk of infection by, transmission of, or accelerated progression of a disease caused by an HIV-1 virus. Diagnostic, prognostic and combined therapeutic kits are also provided. | 01-28-2010 |
20090253919 | Chiral thiourea compounds and process for enantioselective reduction of ketones - Chiral thioureas are effective catalysts for the borane reduction of prochiral ketones to optically active alcohols. A prochiral ketone may be reduced to an optically active alcohol in the presence of a substantially sub-stoichiometric amount of chiral thiourea. The asymmetric thiourea compound of the present invention may be produced according to a production method described herein. | 10-08-2009 |
20090136961 | Novel compositions and methods for identification, assessment, prevention, and therapy of ovarian cancer - The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer. | 05-28-2009 |